M. Matarazzo

A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol

R. Foà, S. Chiaretti, A. Vitale, 2021, Haematologica.

A rare case of compound heterozygosity for delta(+)27 and Hb Neapolis (Dhonburi) associated to an atypical beta-thalassemia phenotype.

V. Poggi, M. Grosso, P. Izzo, 2001, Haematologica.

Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.

R. Foà, A. Vitale, G. Cimino, 2009, Leukemia research.

Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene

R. Foà, M. Vignetti, F. Mandelli, 2011, American journal of hematology.

Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease‐positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial

R. Foà, S. Chiaretti, A. Guarini, 2022, American journal of hematology.

Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase

R. Foà, S. Chiaretti, A. Guarini, 2023, Leukemia & lymphoma.

Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial

S. Chiaretti, L. Elia, P. Fazi, 2023, Blood.